Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty (NCT07214311)
RETAIN: A Phase 2/3 Randomized, Placebo-Controlled Study to Evaluate the Efficacy of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Total Knee Arthroplasty (TKA)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to evaluate whether the investigational drug PLG0206 can help reduce recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR (Debridement, Antibiotics, and Implant Retention) surgical procedure to treat a Prosthetic Joint Infection (PJI). The study will also assess the safety of PLG0206 when used as an irrigation solution during the DAIR procedure. Participants will receive either PLG0206 or a placebo (an inactive substance that looks like the investigational drug), in addition to standard of care treatments. All participants will be monitored for approximately one year following their DAIR procedure.
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Sarasota, Florida
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Clinical Trial Site — Sarasota, Florida
- Clinical Trial Site — Tamarac, Florida
- Clinical Trial Site — Shreveport, Louisiana
- Clinical Trial Site — Baltimore, Maryland
- Clinical Trial Site — Boston, Massachusetts
- Clinical Trial Site — New York, New York
- Clinical Trial Site — Leland, North Carolina
- Clinical Trial Site — Cincinnati, Ohio
- Clinical Trial Site — Cleveland, Ohio
- Clinical Trial Site — Columbus, Ohio
- Clinical Trial Site — Pittsburgh, Pennsylvania
- Clinical Trial Site — Dallas, Texas
- Clinical Trial Site — Edinburg, Texas
- Clinical Trial Site — Salt Lake City, Utah
- Clinical Trial Site — Morgantown, West Virginia
- Clinical Trial Site — Leeds, West Yorkshire
📞 Contact the Study Coordinator
Phone: (412) 643-4924
Email: ClinicalTrials@peptilogics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prosthetic-joint Infection
Explore by condition: All Prosthetic-joint Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.